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Housron. ?e.?;is 
revascularization. This observation implies that positron 
emission tomography does not increase or decrease the 
total number of such patients undergoing revasculmiza- 
tion. 
2. Of 82 patients in the study, 18 (22%) had viable myocar- 
dium but did not undergo revasculariration, suggesting a 
potentially “wrong” clinical decision in light of the sub- 
sequeot 50% event rate in this group; 14 patients (17%) 
bnd revasculariization despite the absence of viable myo- 
cardium a! risk, alsc suggesting a potentially “wrong” 
clinical decision to undertake a possibly unnecessary 
intervertioc. 
The present study. The study by Eitzman et al. (I) in this 
issue of the Journal reports tbe clinical outcome of patients 
with advanced coronary artery disease after cardiac positron 
emission tomography for assessing myocardial viability. 
Their data place current criteria for conxwy revasculariza- 
tiott in such Datients into an imwrtant wsoective and 
contain some &prlsing and sobering info&& that is not 
directly addressed or acknowledged by the authors. 
On the basis of an appropriate retrospective analysis, the 
authors (1) conclude that patients with imoaired left ventric- 
ular function and viable myocardium at hsk as assessed by 
positron emission tomography lwe a high (50%) subsequent 
cardiac event rate in the absence of revasculariration. By 
comparison, the comparable group with viable myocxdium 
at risk by positron emission tomography who underwent 
revascularization had a significantly lower cardiac event rate 
(12%) and greater symptomatic impmvement. Patients with- 
out viable myocardium at risk by positron emission tomog- 
raohv did equallv wall either with or without revasculariza- 
t&t,- the& s&esting that revascularization was not 
necessary. These data strongly support the value of positron 
emission tomography for selecting patients for revascttlar- 
batOIl. 
Analysis of their data in Table t shows tbe following 
additional results that were not noted or addressed: 
I. Of 82 patients in the study, a total of 40 (49%) in fact had 
revascularization; 44 (54%) of these 62 patients needed 
revascularization on the basis of positron emission to. 
mography, thereby suggesting that the total percent of 
such patients needing revawdarization on this basis is 
about the fame ar the total percent actually undergoing 
Thus, on the basis of positron emission tomography, a 
potentially wrong clinical decision was made in I8 + 14 OT 32 
(39%) of 82 patients either for or against revascularlzation 
when the opposite decision was indicated by the tomw 
graphic study. These data imply that using positron emission 
tomography as the basis of a clinical decision for or against 
revascularization would have significantly altered the selec- 
tion ofwbich patients undelwent wwcularization while not 
changing their total number. The data also imply that clinical 
r~~*come would have been significantly be& (12% late 
cardiac events) after revascularization based on positron 
emission tomography versus a 50% cardiac event rate with- 
out positron emission tomography. In effect, positron emis- 
sion tomography would appear to improve the efficiency of 
patient selection for revasculwization. where etIlciency 
means optimal outcome with minimal unnecessary revascu- 
larization procedures. 
Current criteria for coronary nvasculnrhr(ion. This anal- 
ysis raises several questions about the technicaldies, ethics 
and economics of current criteria for revascularization of 
patients with advanced coronary artery disease. If 3% of 
patients in this study had a clinical decision for or against 
revascularization that was inconsistent with myoardial vi- 
ability by positron emission tomography, one might ask what 
were the criteria for revascularization? The clinical circum- 
stances and coronary artery anatomy were not reported that 
may have influenced clinical decisions separate from viabil- 
ity. As noted later, in our experience objective criteria for 
revascularizatian in such patients are oRen diicult to ideb 
tify. 
We recently addressed these same questions about the 
meaning of myocardial viability (2,3) and the percent of 
patients suitable for revascularization on the basis of 
positron emission tomography as compared with the clinical 
decisions actually made. Surprisingly, the data of Eitzmatt et 
al. (I) are quite similar to those in our separate, independent 
study, which included a careful analysis of coronary arteri- 
ognphy (data submitted for publication). In our study, 54% 
of study subjects were suitable for revascularization on the 
basis ofremaining viability by p&tron emission tomography 
combined with coronary arteriography according to clearly 
defined criteria: a clinical decision for or against revzscular- 
izatmn that v as not consislent with these viablhty data wax 
made in 46% of study whw,~ comoarab e IO Lhe 39% in the 
study by hitzman e, al. tl) Thur. !hw two unrrlawi 
studies from different universitv centers using different 
equipment and radionuclides for assessing myocardnl via- 
bility report remarkablv similarfindmcs. Aooroxlmatelv half _ 
of &&Is with adtioceu coronary artery disease have 
sufficient remaining viable myocardwn as arsewd hy 
positron emission tomography io warrant rsvasculariatmn. 
However. current selection of who dues or does no: undergo 
revascularization may be iw irrect in ?9% to 46’: of patients 
as judged by positron emission tomography. 
Clinical implicafions. Should myccardial viahility hy 
positron emission tomogrdphy be the basis for deciding on 
revasculari2ation given appropriate coronary artcry anat. 
omy and clinical conditions? The anwer depends on rhe 
point of view and what is acceptable as scientific proof. .&It 
clinical reports to date on myocardial viability aad wascu- 
larization. including that by Eitzman et al. I IL arc wtm~e~- 
tive analyses or “natural htstory” studies of patient manage- 
ment related to positron emission tomographv performed 
incidentally wi!bout sysemanc cri!crx for or against revas- 
culariation based on Ihe loomgraphic results. 
One point of view holds that only a prospective. random- 
ized trial of revascularization would provide adequate scien- 
tific proof. However, withholding revascularization from a 
patient with viable myocardwm might be an ethical limita 
tion to such a study. As alternative treatment to revascular- 
ization in a randomized trial. strict dietary management and 
cholesterol-lowering drugs are associated with an 8% prob- 
ability of reversal or cessation of progression of coronary 
artery stenosis and a corresponding decrease in clinical 
events (4.5). Therefore. the effectiveness of alternative t’w- 
spy may be sufficient to confound a randomized trial on the 
benefits of selecting patients for revascularizalion based on 
positmn emission tomography. 
Another point of view that is also scientilicatty reasonable 
and avoids these ethical and medical dilemmas holds that 
proof would be provided by a prospective trial (not nndom- 
ized) of performance or nonperformance of revascularina- 
tion on the basis of assessment of myocardial viability by 
positron emission tomography integrated with coronary or- 
teriogmphic findings by specific criteria. By following clini- 
cal outcomes ofmortality, clinical events and lefi ventricular 
function. the benefits and efficiency of selecting patients for 
revasculxization based an viability of positron emission 
tomography would be prospectively demonstrated or ne- 
gated. 
Still another point of view holds that a potentially wrong 
decision for or against revascularization in 3% to 46% of 
patients with advanced coronary artery disease is unaccepr- 
aYe personally, medically and economically. From this 
perspective, the extensive studies (6-15) on the use of 
positron emission tomography far assessin& myocardi~! ria- 
bility establish its validity. The question Jf revascularization 
is a separate one involving a complex teatment with sub- 
Prarticat applications and economic considerations. All of 
thew pomts of view are valid: all are cwrcntly held by 
vilnws components of the medsal-sclentrfic comm,m~,y and 
ail can clam the labet of conscrvalive or pmgrersive quabty 
medwd can’ Given the current rsimbursemenr enwronmem 
wi,h it\ emphasis on reducing unnecessary mcdicat ~rocc. 
durc, and costs. the question wilt probably be &lved 
practdly un erounds of efliciencv. Efficiencv in this con- 
text means opt&l outcomes for minimal overall diagnostic! 
therapeuuc costs by proper selection of patients for revas- 
culnnzation baed on posirron emission tomography 
perfcmxzd at a charge comparable Lo that of current thallium 
Imaging tnon aver&g Zi.Mw to $1.800 per study for all 
cocts m mat large cities in the United States1 (13.14). 
Thus. (be qwtion regarding ~.,sitroo emission tomogra- 
phy and revascularization may not be a conceotual scientific 
one hut rather a question of efficiency or practical appiica- 
lions and economics. Because the cost per positron emisrion 
tomographic sti;dy using gineraior-produced robidmm-a2 is 
subs&muatty less than (hat of revascularizalion and is com- 
parable to that of stress thatlium imagin:. I believe that the 
efficiency question clearly favors pcsiwr e-ission tomog- 
raphy. However, given the range of opinion and medical 
practice derived from any set of facts. some thtrd parry or 
self-Insured payers wilt reoure the prospective “aoplica- 
tions” trial described abov; as a basis fdr reimburs&nr. 
thereby limiung this approach in their insured cticnts. Other 
payers now ree positron emission tomography as an appor- 
tunitv to improve immediatelv the efficiencv of cardiovascu- 
lar &zdicine by minimizing~overall diag$xticltberapeutic 
costs while oplimizing quality care and already reimburse for 
pasilron emission tomography. 
The very questions being asked and the ethical-economic 
complexities themselves suggest that the rote of posrtron 
emission tomography in cardiovascular medicine is already 
established in the heterogeneous pattern characteristic of 
innovations involving lives and money in a competitive, 
multiopinionated society. Having dealt with these questions 
in many hundreds of patients. seen rhe clinical outcomes 
wth and without positron emission tomography and devoted 
a textbook to the topic of cardiac positron emission tomog- 
raphy (15). I myself would consider revasculariratian only 
after cardiac positron emission tomography should I ever 
develop coronary artery disease. 
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